SNGX

Soligenix, Inc. (SNGX) ESG Analysis Analysis (2026)

Invetso Score: 5.5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

SNGX appears to have limited disclosed environmental intensity metrics, which reduces transparency versus larger biotech peers that typically report more complete emissions and resource data.

The company’s low leverage suggests a relatively light capital footprint, but this is not a direct environmental advantage because peers in the sector also tend to be asset-light.

No disclosed R&D-to-revenue spending in the provided metrics limits assessment of laboratory energy and materials efficiency, leaving SNGX broadly in line with smaller peers on disclosure depth.

Absent evidence of material manufacturing or supply-chain environmental exposure, SNGX likely faces fewer direct environmental liabilities than diversified life-science peers with heavier operational footprints.

Social

Score:

SNGX’s small-scale profile likely limits workforce and community exposure, but peers with more mature operations usually provide clearer disclosure on employee health, safety, and retention.

The provided metrics do not show stock-based compensation pressure, which can support internal alignment, yet peer comparison is constrained by limited social disclosure.

As a biotech company, SNGX’s social materiality is concentrated in patient safety, trial conduct, and data integrity, but the available information does not demonstrate peer-leading practices.

Overall social positioning appears average versus peers because limited public metrics reduce visibility into labor, clinical, and stakeholder-management standards.

Governance

Score:

SNGX’s very low debt-to-equity ratio indicates limited balance-sheet leverage, which can reduce creditor pressure and governance complexity versus more indebted peers.

However, the absence of disclosed stock-based compensation and broader governance metrics limits assessment of board discipline, executive incentives, and shareholder alignment.

Smaller biotech peers often face governance scrutiny around dilution and capital allocation, and SNGX’s limited disclosure keeps it from standing out positively on these issues.

Without evidence of persistent controversies or structural control weaknesses, SNGX appears broadly average on governance relative to similarly sized peers.

Overall Score

Score:

SNGX’s ESG positioning is broadly average versus peers, with limited disclosure and no clear structural advantage or disadvantage across the material ESG dimensions.

Score Driver: Limited ESG Disclosure Depth Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Soligenix, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →